Timing of rabbit antithymocyte globulin induction therapy in kidney transplantation: an observational cohort study

Table 3 Linear regression models for mean CKD-EPI eGFR at 12 months and mean delta CKD-EPI eGFR at 1 versus 12 months

Models	Mean CKD-EPI eGFR^abeta coefficient for timing (95% CI)	Mean delta CKD-EPI eGFR^abeta coefficient for timing (95% CI)
1	−1.67 (−6.07, 2.74)	1.52 (−2.06, 5.10)
2	−0.67 (−5.11, 3.77)	0.97 (−2.69, 4.63)
3	1.14 (−2.36, 4.64)	1.62 (−2.16, 5.41)
4	0.88 (−2.51, 4.27)	1.46 (−2.31, 5.23)
5	0.64 (−2.82, 4.11)	1.77 (−2.08, 5.63)

Model 1 = Timing only.
Model 2 = Model 1 + indication (high risk recipient and donor, high risk recipient, high risk donor, low risk recipient and donor).
Model 3 = Model 2 + 1-month recipient eGFR (CKD-EPI) + weight-adjusted total rATG dose + recipient sex + recipient BMI + recipient age + recipient race (Caucasian or non-Caucasian) + cause of ESRD (diabetes or non-diabetes) + time on dialysis + peak PRA + re-graft status.
Model 4 = Model 3 + donor age + donor sex + donor type (living or deceased).
Model 5 = Model 4 + transplant era + occurrence of DGF.
BMI, body mass index; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; DGF, delayed graft function; eGFR, estimated glomerular filtration rate; ESRD, end stage renal disease; PRA, panel reactive antibodies; rATG, rabbit antithymocyte globulin.
^ain mL/min.

ISSN: 2047-1440